SAN DIEGO, 2013-03-07 14:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI)
(www.apricusbio.com) announced today that Edward Cox, Vice President Corporate
Development & Investor Relations, will present at the BIO-Europe Spring 2013
Partnering Conference, being held in Barcelona, Spain. Mr. Cox's presentation
will take place on Wednesday, March 13, 2013 at 11:00 a.m. Local Time (6:00
a.m. Eastern Time).
A replay of the presentation will be accessible to the public online at the Company's website at http://www.apricusbio.com.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China.
For further information on Apricus Bio, visit http://www.apricusbio.com. You can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 david@argotpartners.com
A replay of the presentation will be accessible to the public online at the Company's website at http://www.apricusbio.com.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China.
For further information on Apricus Bio, visit http://www.apricusbio.com. You can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 david@argotpartners.com
© 2013 GlobeNewswire
